Company intelligence / Profile preview

Esphera SynBio

Ottawa, Ontario, Canadaespherasynbio.ca ↗

Ownership: Private
Development stage: Preclinical

Overview

Esphera SynBio is developing a platform that produces engineered exosomes through proprietary transgenes. Their lead application modifies tumor cells in vivo to convert immunosuppressive tumor-derived exosomes into immunostimulatory, antigen-bearing modifiers that act as bespoke cancer vaccines. They are also working on enhancing mRNA vaccine efficacy for infectious diseases.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Engineered exosomesnanomedicinesmRNA vaccinestransgenes
Industry: Biotech

Partnerships

Global biopharmaceutical organization (unnamed)CQDM

Beyond the preview

Go deeper on Esphera SynBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Esphera SynBio.

Explore the full profile